| Programs | Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| Personalized Cancer Vaccine: Intratumoral (PDNA emm55) | |||||
| IFx-Hu2.0 | 1st Line Merkel Cell Pembro +/- IFx-Hu2.0 |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase complete
|
Phase 3 Phase in progress
|
| Primary Checkpoint Inhibitor Resistant Metastatic Cancer "Basket" Trial |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 3 Phase not started
|
|
| Personalized Cancer Vaccine: Intravenous Targeted (mRNA emm55) | |||||
| IFx-Hu3.0 scFv-LNP-mRNA |
Diffuse Large B-Cell Lymphoma (DLBCL) |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
| Tumor Microenvironment Modulators: MDSC Bi-Functional Inhibitors | |||||
| Nal - anti TIGIT Nal - OX40 |
Myelodysplasia Acute Myeloid Leukemia |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Immune Fx (IFx) Personalized Cancer Vaccines
Key Technology Benefits
- Increases T-cell infiltration in treated and untreated lesions (abscopal effect)
- Leads to production of IgM and IgG with epitope recognition to hundreds of new tumor-associated antigens
- Gene signature associated with innate response in the injected lesions (CXCL13, LAG3, CXCL11, CXCL10, ICOS)
- Gene signature associated with adaptive response in un-injected lesions (IL-12, HLA-DRB5, WNT4, CD3D, Arg I)
Tumor Microenvironment Modulators
Key Technology Benefits
- Blocks myeloid derived suppressor cell (MDSC) production of multiple immune suppressing soluble factors
- Converts tumorigenic (tumor growth and spread) microenvironment to immunogenic (immune cell infiltration and attack)
- Prevents immune cell exhaustion (T-cell, NK cell, CAR-T)
- Overcomes resistance to checkpoint inhibitors
- Increases safety and efficacy of immuno- and cellular-therapy